Survival Rates Up in Primary Cutaneous Diffuse Large B-cell Lymphoma

Patients with primary cutaneous diffuse large B-cell lymphoma, leg type, experienced the best survival rates with rituximab and combination chemotherapy, according to a new study.

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT), is known to occur in elderly patients and does not have a good prognosis. The estimated 5-year survival rate is approximately 50 percent.

French researchers retrospectively studied 115 patients with a mean age of 76.9 diagnosed with PCDLBCL-LT between 1988 and 2003, and 2004 and 2010 and who received polychemotherapy (PCH) or PCH plus rituximab.

Age, sex, diagnosis time period, number of skin lesions, tumor stage, location, lactate dehydrogenase level and type of therapy and outcome were recorded. Mean follow-up was 39 months.

Survival rates were significantly higher in the later group. Rates of 3 and 5 years were 80 percent and 74 percent respectively when treated with rituximab-polychemotherapy (PCT), compared to 48 percent and 38 percent respectively in patients treated with less-intensive therapies.

Disease-related death was significantly associated with location on the leg and treatment without rituximab-PCT.

Source: JAMA Dermatology

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap